Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Has Consensus Target Price of $33.71 According to Brokerages

Posted by Stanley Muller on Oct 7th, 2026

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) has been given an average rating of “Moderate Buy” by the nine brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $33.71.

A number of analysts recently weighed in on CGEM shares. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Cullinan Therapeutics in a report on Friday, October 2nd. BTIG Research reissued a “buy” rating and set a $40.00 target price on shares of Cullinan Therapeutics in a research note on Friday, September 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Cullinan Therapeutics in a research note on Wednesday, July 8th. Wedbush lifted their price target on Cullinan Therapeutics from $39.00 to $42.00 and gave the company an “outperform” rating in a report on Thursday, August 13th. Finally, TD Cowen upgraded Cullinan Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th.

Read Our Latest Analysis on Cullinan Therapeutics

Key Cullinan Therapeutics News

Here are the key news stories impacting Cullinan Therapeutics this week:

Positive Sentiment: HC Wainwright raised its EPS estimates across several periods, including Q3 2026 to $(0.86) from $(0.90), Q4 2026 to $(0.89) from $(0.93), and FY2026 to $(3.45) from $(3.53). The firm also sharply improved its FY2027 forecast to a $(1.81) loss from $(3.89), with its model now projecting positive EPS of $0.39 in Q4 2027. The revisions suggest improving expectations for Cullinan’s earnings trajectory and supported the stock’s advance. HC Wainwright Has Optimistic Opinion of CGEM Q3 Earnings
Neutral Sentiment: Despite the upward estimate revisions, Cullinan is still expected to report losses in most quarters, including a $(3.45) per-share loss for FY2026 and a $(1.81) loss for FY2027. The company’s current-year consensus forecast remains a $(3.08) per-share loss, so investors will likely continue focusing on clinical progress, cash resources and the path toward profitability.
Negative Sentiment: HC Wainwright’s improved outlook does not eliminate near-term earnings risk; the company remains unprofitable and its shares were still trading below their 50-day moving average, indicating that broader investor confidence has not fully recovered.

Cullinan Therapeutics Price Performance

NASDAQ:CGEM opened at $16.25 on Friday. The firm has a market capitalization of $1.05 billion, a P/E ratio of -5.24 and a beta of -0.05. The business has a 50 day simple moving average of $19.48 and a 200 day simple moving average of $16.78. Cullinan Therapeutics has a 12-month low of $5.71 and a 12-month high of $23.19.

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.01). Research analysts anticipate that Cullinan Therapeutics will post -3.06 EPS for the current fiscal year.

Insiders Place Their Bets

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of the business’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $21.57, for a total transaction of $172,560.00. Following the completion of the transaction, the insider owned 158,844 shares in the company, valued at approximately $3,426,265.08. The trade was a 4.79% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 8.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CGEM. BlackRock Inc. acquired a new stake in Cullinan Therapeutics in the second quarter worth about $95,289,000. Blue Owl Capital Holdings LP acquired a new position in Cullinan Therapeutics during the 2nd quarter valued at about $28,039,000. Boothbay Fund Management LLC bought a new stake in shares of Cullinan Therapeutics during the 4th quarter worth about $12,803,000. Dimensional Fund Advisors LP raised its position in shares of Cullinan Therapeutics by 6.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 906,028 shares of the company’s stock worth $12,870,000 after buying an additional 57,259 shares in the last quarter. Finally, Boone Capital Management LLC acquired a new stake in shares of Cullinan Therapeutics in the 2nd quarter worth approximately $12,828,000. 86.31% of the stock is owned by institutional investors and hedge funds.

About Cullinan Therapeutics

(Get Free Report)

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer and autoimmune diseases. The company uses a portfolio-based approach to advance targeted therapies and immune-modulating treatments intended to address significant unmet medical needs.

Cullinan’s pipeline includes zovoltamab brengitecan (CLN-978), an investigational CD19-directed T-cell engager being studied in B-cell malignancies and autoimmune conditions, and CLN-619, an investigational antibody designed to target MICA and MICB proteins and stimulate anti-tumor immune responses.